Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More
BIOCON | SANOFI INDIA | BIOCON / SANOFI INDIA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | 41.3 | 60.9% | View Chart |
P/BV | x | 3.3 | 7.2 | 46.0% | View Chart |
Dividend Yield | % | 0.3 | 1.2 | 28.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-18 |
SANOFI INDIA Dec-18 |
BIOCON / SANOFI INDIA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,188 | 6,840 | 17.4% | |
Low | Rs | 305 | 4,630 | 6.6% | |
Sales per share (Unadj.) | Rs | 68.7 | 1,203.1 | 5.7% | |
Earnings per share (Unadj.) | Rs | 7.6 | 165.3 | 4.6% | |
Cash flow per share (Unadj.) | Rs | 14.0 | 209.9 | 6.7% | |
Dividends per share (Unadj.) | Rs | 1.00 | 84.00 | 1.2% | |
Dividend yield (eoy) | % | 0.1 | 1.5 | 9.1% | |
Book value per share (Unadj.) | Rs | 86.3 | 963.6 | 9.0% | |
Shares outstanding (eoy) | m | 600.00 | 23.03 | 2,605.3% | |
Bonus/Rights/Conversions | IS | - | - | ||
Price / Sales ratio | x | 10.9 | 4.8 | 227.9% | |
Avg P/E ratio | x | 98.9 | 34.7 | 284.9% | |
P/CF ratio (eoy) | x | 53.4 | 27.3 | 195.5% | |
Price / Book Value ratio | x | 8.6 | 6.0 | 145.3% | |
Dividend payout | % | 13.2 | 50.8 | 26.1% | |
Avg Mkt Cap | Rs m | 447,900 | 132,078 | 339.1% | |
No. of employees | `000 | 6.1 | 3.3 | 186.3% | |
Total wages/salary | Rs m | 9,311 | 4,068 | 228.9% | |
Avg. sales/employee | Rs Th | 6,705.8 | 8,393.8 | 79.9% | |
Avg. wages/employee | Rs Th | 1,514.2 | 1,232.4 | 122.9% | |
Avg. net profit/employee | Rs Th | 736.9 | 1,153.0 | 63.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 41,234 | 27,708 | 148.8% | |
Other income | Rs m | 2,062 | 897 | 229.9% | |
Total revenues | Rs m | 43,296 | 28,605 | 151.4% | |
Gross profit | Rs m | 8,291 | 6,235 | 133.0% | |
Depreciation | Rs m | 3,851 | 1,027 | 375.0% | |
Interest | Rs m | 615 | 7 | 8,785.7% | |
Profit before tax | Rs m | 5,887 | 6,098 | 96.5% | |
Minority Interest | Rs m | 213 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,569 | 2,292 | 68.5% | |
Profit after tax | Rs m | 4,531 | 3,806 | 119.0% | |
Gross profit margin | % | 20.1 | 22.5 | 89.4% | |
Effective tax rate | % | 26.7 | 37.6 | 70.9% | |
Net profit margin | % | 11.0 | 13.7 | 80.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 41,486 | 15,922 | 260.6% | |
Current liabilities | Rs m | 21,413 | 6,235 | 343.4% | |
Net working cap to sales | % | 48.7 | 35.0 | 139.2% | |
Current ratio | x | 1.9 | 2.6 | 75.9% | |
Inventory Days | Days | 64 | 64 | 100.5% | |
Debtors Days | Days | 94 | 21 | 451.3% | |
Net fixed assets | Rs m | 50,661 | 7,539 | 672.0% | |
Share capital | Rs m | 3,000 | 230 | 1,304.3% | |
"Free" reserves | Rs m | 48,808 | 21,962 | 222.2% | |
Net worth | Rs m | 51,808 | 22,192 | 233.5% | |
Long term debt | Rs m | 17,898 | 0 | - | |
Total assets | Rs m | 99,897 | 29,839 | 334.8% | |
Interest coverage | x | 10.6 | 872.1 | 1.2% | |
Debt to equity ratio | x | 0.3 | 0 | - | |
Sales to assets ratio | x | 0.4 | 0.9 | 44.5% | |
Return on assets | % | 5.2 | 12.8 | 40.3% | |
Return on equity | % | 8.7 | 17.2 | 51.0% | |
Return on capital | % | 9.6 | 27.5 | 35.0% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 12,058 | 7,587 | 158.9% | |
Fx outflow | Rs m | 7,348 | 7,145 | 102.8% | |
Net fx | Rs m | 4,710 | 442 | 1,065.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 6,621 | 3,739 | 177.1% | |
From Investments | Rs m | -6,840 | -731 | 935.7% | |
From Financial Activity | Rs m | -2,397 | -1,972 | 121.6% | |
Net Cashflow | Rs m | -2,612 | 1,036 | -252.1% |
Indian Promoters | % | 40.4 | 0.0 | - | |
Foreign collaborators | % | 20.6 | 60.4 | 34.1% | |
Indian inst/Mut Fund | % | 8.4 | 14.4 | 58.3% | |
FIIs | % | 10.7 | 14.6 | 73.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 19.9 | 10.5 | 189.5% | |
Shareholders | 109,995 | 15,184 | 724.4% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON With: CADILA HEALTHCARE SUVEN LIFESCIENCES CIPLA WOCKHARDT VENUS REMEDIES
Compare BIOCON With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
| |
Share markets in India are presently trading on a negative note. Investors turned cautious ahead of global as well as domestic macroeconomic data release.
For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsA single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.
What we can learn from one of the greatest traders to have ever lived.
Should you invest in growth stocks or value stocks to make strong returns in this market?
Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.
The lowest hanging fruit for government to raise capital would be to sell off stakes in non-critical PSUs.
More